The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain
- 22 September 2004
- journal article
- clinical trial
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 131 (1) , 60-66
- https://doi.org/10.1007/s00432-004-0625-0
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- 153 Sm-EDTMP for bone pain palliation in skeletal metastasesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2004
- Rhenium-188-HEDP Therapy for the Palliation of Pain Due to Osseous Metastases in Lung Cancer PatientsCancer Biotherapy & Radiopharmaceuticals, 2003
- Repeated Bone-Targeted Therapy for Hormone-Refractory Prostate Carcinoma: Randomized Phase II Trial With the New, High-Energy Radiopharmaceutical Rhenium-188 HydroxyethylidenediphosphonateJournal of Clinical Oncology, 2003
- Pain Measurement Tools and Methods in Clinical Research in Palliative CareJournal of Pain and Symptom Management, 2002
- Update Palliative Therapy with Bone Seeking RadiopharmaceuticalsCancer Biotherapy & Radiopharmaceuticals, 1998
- The Karnofsky performance status scale re-examined: a cross-validation with the EORTC-C30Quality of Life Research, 1994
- Targeted radionuclide therapy for bone metastasesEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993
- A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonateEuropean Journal of Cancer and Clinical Oncology, 1991
- Samarium ? 153 EDTMP therapy of disseminated skeletal metastasisEuropean Journal of Nuclear Medicine and Molecular Imaging, 1989
- Die Yttrium-90-Therapie von KnochenmetastasenDeutsche Medizinische Wochenschrift (1946), 1982